ArticleMolecular therapy. Nucleic acids2022

Development of a novel PROTAC using the nucleic acid aptamer as a targeting ligand for tumor selective degradation of nucleolin.

Lin Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.